Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03143374
PHASE2/PHASE3

PET Tau - Neurodegenerative Disease Imaging

Sponsor: University of Pennsylvania

View on ClinicalTrials.gov

Summary

The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). Tau has been shown to build up in the brains of patients with injury to brain cells. This study looks at neurodegenerative diseases such as frontotemporal degeneration (FTD).

Official title: Positron Emission Tomography (PET) Imaging of Tau Pathology in Neurodegenerative Disease

Key Details

Gender

All

Age Range

18 Years - 100 Years

Study Type

INTERVENTIONAL

Enrollment

300

Start Date

2016-08-23

Completion Date

2030-09

Last Updated

2025-10-15

Healthy Volunteers

Yes

Interventions

DRUG

18F-AV-1451

The experimental tracer used for this study is called 18F-AV-1451 is a specialized radioactive PET tracer used to detect the presence of tau proteins in the brain. Participants will undergo a baseline 18F-AV-1451 brain scan. If funding is available, participants will be asked to return for one or more longitudinal visits, including a 18F-AV-1451 brain scan, every 9 to 18 months after the prior visit. The 18F-AV-1451 PET/CT scan will require up to 3 hours of time, including preparation. The scan will take place using PET/CT scanners in the Perelman Center for Advanced Medicine or the Hospital of the University of Pennsylvania.

Locations (1)

University of Pennsylvania

Philadelphia, Pennsylvania, United States